Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
December 05, 2024 08:00 ET | Source: Theriva Biologics, Inc. ROCKVILLE, Md.,…
Search
Have an existing account?
Sign In
Tag: NYSE:TOVX